Clinical Trials Browser

Phase 1/2 × INDUSTRY × Tuberous Sclerosis × Clear all

NCT07287202 2025-12-23

Safety, Tolerability, and Pharmacokinetics of SVG103 (Paxalisib) in Focal Cortical Dysplasia Type II (FCD-II), Tuberous Sclerosis Complex (TSC) or Hemimegalencephaly (HME)

Phase 1/2 Not yet recruiting

Focal Cortical Dysplasia, Tuberous Sclerosis, Hemimegalencephaly

NCT06392009 2025-07-03

Astroscape: A Study of Radiprodil on Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms in Patients With TSC or FCD Type II

Phase 1/2 Recruiting

Focal Cortical Dysplasia, Tuberous Sclerosis